



IJRASET

International Journal For Research in
Applied Science and Engineering Technology



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 13 **Issue:** III **Month of publication:** March 2025

DOI: <https://doi.org/10.22214/ijraset.2025.67326>

www.ijraset.com

Call:  08813907089

E-mail ID: ijraset@gmail.com

Sildenafil Oral Medication for Erectile Dysfunction - A Review

Mrs. Smriti Mathur


Assistant Professor, M.Pharm (Pharmaceutics), Advance Group of Colleges, Naramau Kanpur

Abstract: A Common Drug That Is A Member Of The Phosphodiesterase-5 Inhibitor (Pde5-I) Class Is Sildenafil. It Is Mainly Prescribed To Treat Pulmonary Arterial Hypertension (Pah) And Erectile Dysfunction (Ed). This Study Offers A Thorough Analysis Of Sildenafil, Emphasising Its Pharmacological Underpinnings, Therapeutic Uses, And Modes Of Action. Furthermore, The Paper Addresses The Possible Negative Consequences And Contraindications Related To Its Application. To Effectively Manage Linked Disorders And Optimise Patient Care, Healthcare Providers Must Have A Complete Awareness Of These Aspects. In Order To Get The Best Possible Treatment Results With Sildenafil, The Study Emphasises The Significance Of Proper Patient Selection And Monitoring. By Raising The Amount Of Cyclic Guanosine Monophosphate In The Corpora Cavernosa, The Particular Phosphodiesterase Type V Inhibitor Sildenafil Improves Erection Upon Sexual Stimulation. This Has Completely Changed How Erectile Dysfunction Is Treated. Even While The Medication Seems Highly Promising And Has Few Side Effects, There Are Still A Lot Of Concerns About Its Safety, Effectiveness, And Potential For Abuse And Overuse.

Keywords: Pde5 Inhibitors, Pulmonary Arterial Hypertension, Erectile Dysfunction, Sildenafil, Pharmacology, Side Effects, Contraindications, And Clinical Management

I. INTRODUCTION

Sildenafil is one medication that is commonly used to treat and manage pulmonary arterial hypertension (Pah) and erectile dysfunction (Ed). A member of the phosphodiesterase-5 inhibitor (Pde5-I) class, sildenafil relaxes penile muscles by enhancing the effects of nitric oxide, a substance the body naturally produces. This process facilitates blood flow in response to sexual stimulation, making it easier to get and maintain an erection. Additionally, by relaxing the blood vessels in the lungs, sildenafil helps treat PH by facilitating easier blood flow and reducing the strain on the heart muscle.



With a molecular weight of 666.7 and a solubility of 3.5 mg/ml in water, sildenafil citrate is a white to off-white crystalline powder. For oral administration, Viagra (sildenafil citrate) is formulated in blue, film-coated, rounded, diamond-shaped tablets that contain 25 mg, 50 mg, and 100 mg of sildenafil. Each tablet contains the following inactive ingredients in addition to the active ingredient, sildenafil citrate: Anhydrous dibasic calcium phosphate, croscarmellose sodium, magnesium stearate, hypromellose, lactose, triacetin, and microcrystalline cellulose.

Giving a comprehensive overview of sildenafil, including its indications, mode of action, potential side effects, and contraindications, is the aim of this activity. These factors must be thoroughly understood by healthcare professionals who treat and manage patients with pulmonary arterial hypertension, erectile dysfunction, or related conditions.

Sildenafil, a drug developed by Pfizer®, was being researched as an anti-hypertensive and anti-anginal drug. Despite being a disappointing antihypertensive medication, a number of Participants in the study reported having their best sex in a long time. This prompted further investigation into its potential as a treatment for erectile dysfunction.

II. MECHANISM OF ACTION

For a normal penile erection, the smooth muscles of the corpora cavernosa must relax. Guanylate Cyclase Produces Cyclic Guanosine Monophosphate (Cyclic Gmp) When Cavernous Neurones and Endothelial Cells Release Nitric Oxide (No) in Response to Sexual Stimuli. Sildenafil is ten times more effective against Pde6, an enzyme found in the retina that is thought to be crucial for phototransduction, than it is against Pde1, 2, 3, and 4. Higher dosages are believed to result in colour vision issues, which are thought to be brought on by this decreased sensitivity. Sildenafil only works when there is a partial erection. However, in cases of severe arteriogenic or venogenic impotence, corporal smooth muscle fibrosis, or anatomical penile malformations or anomalies, Elevated Cgmp levels activate Cgmp-Dependent Protein Kinase, which phosphorylates several targets within smooth muscle cells. This cascade results in smooth muscle relaxation, a decrease in intracellular calcium levels, an increase in potassium efflux, and the inactivation of myosin light chain kinase. In The Corpus Cavernos Cgmp-Dependent Protein Kinase is activated by elevated Cgmp levels, phosphorylating many targets in smooth muscle cells. This sequence causes myosin light chain kinase to become inactive, smooth muscle to relax, intracellular calcium levels to drop, and potassium efflux to rise. When sexual stimulation results in the local release of no, sildenafil's inhibition of Pde5 raises Cgmp levels in the corpus cavernosum, which relaxes smooth muscles and allows blood to flow to the area. When sexual stimulation is absent, sildenafil at recommended dosages has no effect.

III. ADMINISTRATION & DOSAGE

A. Erectile Dysfunction

For the maximum individual, 50 mg taken orally as needed, about an hour before sexual activity, is the recommended dosage. However, you can take sildenafil anywhere from 30 to 4 hours before having sex. The highest recommended dosage is one dose per day. Depending on the result and tolerance, the dosage may be reduced to 25 mg or increased to the maximum recommended dose of 100 mg. Erectile Dysfunction: Sildenafil is available as oral tablets in dosages of 25, 50, and 100 mg to treat erectile dysfunction (Ed). The standard starting dosage is 50 mg, which should be taken as needed around one hour before engaging in sexual activity. The patient's response and tolerance will determine whether the dosage is reduced to 25 mg or increased to a maximum of 100 mg. It's important to keep in mind that the maximum recommended dosage frequency is once daily. You can take sildenafil anywhere from 30 to 4 hours prior to your planned sexual activity. The effects can last up to eighteen hours, and the action usually starts within thirty minutes.

B. Pulmonary Arterial Hypertension

The pulmonary arteries are hypertensive. To treat pulmonary arterial hypertension (Pah), sildenafil is available in several forms, such as 20 mg oral tablets, 10 mg/ml oral suspension, and 10 mg/12.5 ml injectable solution. A dosage of 5 mg or 20 mg should be taken three times a day, separated by 4 to 6 hours, for both the pill and the oral suspension form. The injectable form is administered as an intravenous bolus in doses of 2.5 mg or 10 mg three times a day, separated by four to six hours. It is specifically advised that patients undergoing oral sildenafil therapy who are momentarily unable to take their medication use the injectable form.

Paediatric Patients: Larger dosages of sildenafil have been shown in clinical trials to increase mortality in paediatric patients with pah, with deaths occurring approximately a year after initiation. As a result, long-term use of sildenafil in paediatric patients is not advised.

C. Pregnant Women

If their conditions are not addressed, pregnant women with PAH are at serious risk for stroke, heart failure, premature delivery, and maternal and foetal death. Despite the lack of well-controlled trials on sildenafil in pregnant women, small case studies suggest a low risk of harm. Nonetheless, women who are pregnant should use caution when taking sildenafil.

Breastfeeding Women: The effects of sildenafil on breast milk production and breastfed babies are currently poorly understood. As a result, it is advised to provide nursing mothers sildenafil with caution.

D. Pharmacokinetics And Metabolism

Following oral administration, Viagra is quickly absorbed, with an average absolute bioavailability of 41% (range: 25–63%). Over the recommended dosage range, its pharmacokinetics are dose-proportional. Hepatic metabolism, primarily cytochrome P450 3A4, eliminates it mostly and transforms it into an active metabolite with characteristics akin to those of its parent, sildenafil. Increased plasma levels of sildenafil are linked to the concurrent use of strong cytochrome P450 3A4 inhibitors (such as erythromycin, ketoconazole, and itraconazole) and the nonspecific cytop inhibitor cimetidine (see dosage and administration). The terminal half-lives of sildenafil and the metabolite are approximately four hours.

E. Absorption And Distribution

The absorption of Viagra is quick. In the fasted state, the highest observed plasma concentrations are reached 30 to 120 minutes (median 60 minutes) after oral dosing. The rate of absorption is decreased when taking Viagra with a high-fat meal; on average, there is a 60-minute delay in T_{max} and a 29% reduction in C_{max}. Sildenafil's mean steady state volume of distribution (V_{ss}), which shows tissue distribution, is 105 L. Around 96% of sildenafil and its main circulating N-Desmethyl metabolite are bound to plasma proteins. Protein Binding Is Unaffected by Total Drug Levels.

F. Metabolism And Excretion:

The hepatic microsomal enzymes Cyp3a4 (the major route) and Cyp2c9 (the minor route) are primarily responsible for the clearance of sildenafil. N-demethylation of sildenafil produces the main circulating metabolite, which is then further metabolised. This metabolite has an in vitro potency for Pde5 of around 50% of the parent drug and a Pde selectivity profile comparable to that of sildenafil. About 20% of the pharmacologic effects of sildenafil are attributed to this metabolite, as its plasma concentrations are about 40% of those observed for sildenafil. Sildenafil is mostly eliminated as metabolites in the faeces (about 80% of the oral dose) and to a lesser degree in the urine following oral or intravenous administration.

G. Adverse Effect

In Clinical Trial the Most Common Adverse Effect of Sildenafil Use Includes-

- ❖ Headache
- ❖ Flushing
- ❖ Indigestion
- ❖ Nasal Congestion
- ❖ Photophobia

H. Therapeutic Trials

In the US and the UK, the first placebo-controlled pilot experiments revealed a markedly enhanced erection response to visual sexual stimulation. Phase I, II, and III clinical studies in the US and other countries came next. A variety of research were conducted, including single blind, placebo run-in to double blind phase, fixed dose versus dose escalation, and long-term open-label extension trials. Men over the age of 18 who had been diagnosed with both organic and psychogenic erectile dysfunction participated in the research. Responses to questions three (frequency of penetration) and four (maintenance of erection after penetration) of the 15-question International Index of Erectile Function questionnaire were used to evaluate efficacy.

On a scale of 1 (nearly seldom or never) to 5 (almost always or always), the answers to the aforementioned questions were scored. The sexual partners were interviewed for a large number of the research. Every study demonstrated that sildenafil continuously enhanced erectile function and boosted sexual arousal alone by three to four times. An hour prior to the planned sexual activity, the majority of men took the drug. Both the frequency and intensity of sexual desire were not increased by the drug, nor did it raise non-sexual "waking" erections.

Sildenafil tripled the success of sexual activity and considerably improved erectile function in 861 patients with erectile dysfunction of different causes, according to a multicenter double blind randomised trial. The effects of the medication lasted for at least six months.

57% of Sildenafil users reported that the medication enhanced their erections, compared to 10% of placebo users in a trial of patients with diabetes mellitus and erectile dysfunction. Sildenafil increased erections and participants' satisfaction with their sex life in a small, randomised investigation of erectile dysfunction patients with spinal cord injuries.

I. New Areas of Research

Pfizer is already developing a sildenafil wafer composition that will have an almost instantaneous effect. Apomorphine and phentolamine are two other medications being explored as oral pills for impotence. Both, meanwhile, haven't showed much promise in preliminary testing. Prostaglandin E1, or aprocastil, is being tested as a topical gel and an intraurethral pessary. Numerous studies are being conducted to determine whether sildenafil can improve a woman's sex. Women are known to have erectile tissues as well, and many experts now think that the reasons of male and female impotence might not be so dissimilar. Phase II trials for the use of sildenafil in women are now underway in Europe.

IV. CONCLUSION

For a long time, millions of men have been silently hoping for a straightforward treatment that would help them get or keep an erection. The first significant advancement in the treatment of erectile dysfunction was the introduction of intracavernous injection of vasoactive materials for erection in 1983. The ultimate objective, according to the American Urological Association Panel on the Treatment of Organic Erectile Dysfunction, is a treatment that is easy to use, dependable, and has few adverse effects. It seems that sildenafil satisfies these requirements.

Compared to certain alternative treatment methods such injections into the corpus cavernosum, transurethral medication delivery, and penile prosthesis implantation, oral therapy allows for inconspicuous administration and is less invasive. Over time, additional information regarding the safety and effectiveness of sildenafil is probably going to surface because to its extensive use. These medications are probably going to help women have more fulfilling sex as well.

REFERENCES

- [1] Hatzimouratidis K, Eardley I, Giuliano F, Et Al. Guidelines On Male Sexual Dysfunction: Erectile Dysfunction And Premature Ejaculation. 2014. Available From: <https://Uroweb.Org/Guideline/Male-Sexual-Dysfunction/>. Accessed June 20, 2016.
- [2] Hakky Ts, Jain L. Current Use Of Phosphodiesterase Inhibitors In Urol Ogy. Turk J Urol. 2015;41(2):88.
- [3] Smith Wb 2nd, Mccaslin Ir, Gokce A, Mandava Sh, Trost L, Hellstrom Wj. Pde5 Inhibitors: Considerations For Preference And Long-Term Adherence. Int J Clin Pract. 2013;67(8):768–780.
- [4] Alwaal A, Al-Mannie R, Carrier S. Future Prospects In The Treatment Of Erectile Dysfunction: Focus On Avanafil. Drug Des Devel Ther. 2011;5: 435–443.
- [5] Limin M, Johnsen N, Hellstrom Wj. Avanafil, A New Rapid-Onset Phosphodiesterase 5 Inhibitor For The Treatment Of Erectile Dysfunction. Expert Opin Investig Drugs. 2010;19(11):1427–1437.
- [6] Leoni La, Leite Gs, Wichi Rb, Rodrigues B. Sildenafil: Two Decades Of Benefits Or Risks? Aging Male. 2013;16(3):85–91.
- [7] Goel H, Rai P, Rana V, Tiwary Ak. Orally Disintegrating Systems: Inno Vations In Formulation And Technology. Recent Pat Drug Deliv Formul. 2008;2(3):258–274.
- [8] Heinig R, Weimann B, Dietrich H, Bottcher Mf. Pharmacokinetics Of A New Orodispersible Tablet Formulation Of Vardenafil: Results Of Three Clinical Trials. Clin Drug Investig. 2011;31(1):27–41.
- [9] Debruyne Fm, Gittelman M, Sperling H, Borner M, Beneke M. Time To Onset Of Action Of Vardenafil: A Retrospective Analysis Of The Pivotal Trials For The Orodispersible And Film-Coated Tablet Formulations. J Sex Med. 2011;8(10):2912–2923.
- [10] Sperling H, Debruyne F, Boermans A, Beneke M, Ulbrich E, Ewald S. The Potent I Randomized Trial: Efficacy And Safety Of An Orodispersible Vardenafil Formulation For The Treatment Of Erectile Dysfunction. J Sex Med. 2010;7(4 Pt 1):1497–1507
- [11] Gittelman M, McMahon Cg, Rodriguez-Rivera Ja, Beneke M, Ulbrich E, Ewald S. The Potent Ii Randomised Trial: Efficacy And Safety Of An Orodispersible Vardenafil Formulation For The Treatment Of Erectile Dysfunction. Int J Clin Pract. 2010;64(5):594–603. Drug Design, Development And Therapy Downloaded From <https://www.dovepress.com/> By 191.96.170.248 On 17-Aug-2018 For Personal Use Only.
- [12] Sperling H, Gittelman M, Norenberg C, Ulbrich E, Ewald S. Efficacy And Safety Of An Orodispersible Vardenafil Formulation For The Treatment Of Erectile Dysfunction In Elderly Men And Those With Underlying Con Ditions: An Integrated Analysis Of Two Pivotal Trials. J Sex Med. 2011; 8(1):261–271.
- [13] Thakur N, Bansal M, Sharma N, Yadav G, Khare P. Overview “A Novel Approach Of Fast Dissolving Films And Their Patents”. Adv Biol Res (Rennes). 2013;7(2):50–58.
- [14] Irfan M, Rabel S, Bukhtar Q, Qadir Mi, Jabeen F, Khan A. Orally Dis Integrating Films: A Modern Expansion In Drug Delivery System. Saudi Pharm J. 2015;24(5):537–546.
- [15] Kathpalia H, Gupte A. An Introduction To Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review. Curr Drug Deliv. 2013;10(6): 667–684.
- [16] Hoffmann Em, Breitenbach A, Breikreutz J. Advances In Orodispersible Films For Drug Delivery. Expert Opin Drug Deliv. 2011;8(3): 299–316.
- [17] European Pharmacopoeia. 2014, 8th Edition, Orodispersible Films. Available From: <http://online6.edqm.eu/ep802/>. Accessed July 8, 2016
- [18] Roh H, Son H, Lee D, Et Al. Pharmacokinetic Comparison Of An Orally Disintegrating Film Formulation With A Film-Coated Tablet Formulation Of Sildenafil In Healthy Korean Subjects: A Randomized, Open-Label, Single Dose, 2-Period Crossover Study. Clin Ther. 2013;35(3):205–214.
- [19] Muirhead GJ, Wilner K, Colburn W, Haug-Pihale G, Rouviex B. The Effects Of Age And Renal And Hepatic Impairment On The Pharmacokinetics Of Sildenafil. Br J Clin Pharmacol. 2002;53(Suppl 1):21s–30s.
- [20] Garnero C, Chattah Ak, Longhi M. Supramolecular Complexes Of Maltodextrin And Furosemide Polymorphs: A New Approach For Delivery Systems. Carbohydr Polym. 2013;94(1):292–300.
- [21] Doggrell S. Do Vardenafil And Tadalafil Have Advantages Over Sildenafil In The Treatment Of Erectile Dysfunction? Int J Impot Res. 2007;19(3): 281–295.
- [22] Hackett Gi. Patient Preferences In Treatment Of Erectile Dysfunction: The Continuing Importance Of Patient Education. Clin Cornerstone. 2005; 7(1):57–65.
- [23] Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil And Vardenafil Vs Sildenafil: A Review Of Patient-Preference Studies. Bju Int. 2009; 103(9):1212–1217.
- [24] Raheem Aa, Kell P. Patient Preference And Satisfaction In Erectile Dysfunction Therapy: A Comparison Of The Three Phosphodiesterase-5 Inhibitors Sildenafil, Vardenafil And Tadalafil. Patient Prefer Adherence. 2009;3:99–104
- [25] NIH Consensus Development Panel on Impotence. JAMA. 1994;270:83–90. [\[PubMed\]](#) [\[Google Scholar\]](#)
- [26] Lanet OL, Ogrine PG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996;334:873-7 [\[DOI\]](#) [\[PubMed\]](#)
- [27] Padma-Nathan H, Hellstrom WJG, Kaiser FE. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336:1–7. doi: 10.1056/NEJM199701023360101. [\[DOI\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)
- [28] Montague DK, Barada JH, Belkar AM. Clinical Guidelines Panel on Erectile Dysfunction: Summary report on treatment of organic erectile dysfunction. J Urol 1996;156:2007-11 [\[DOI\]](#) [\[PubMed\]](#)



- [29] Andersson KE, Wagner G. Physiology of penile erection. *Physiol Rev.* 1995;75:191–236. doi: 10.1152/physrev.1995.75.1.191. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
- [30] Burnett AL. The role of nitric oxide in the physiology of erection. *Biol Reprod* 1995;52:485-9 [[DOI](#)] [[PubMed](#)]
- [31] Boolell M, Allel MJ, Ballard SA, et al. Sildenafil: an orally active type V cyclic GMP specific phosphodiesterase inhibitor for treatment of penile erectile dysfunction. *Int J Impot Res* 1996;8:47-52 [[PubMed](#)]
- [32] Boolell M, Gepi Attee S, Gingell GC, Allen MJSildenafil, a novel effective oral therapy for male erectile dysfunction. *Br J Urol.* 1996;78:257–261. doi: 10.1046/j.1464-410x.1996.10220.x. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
- [33] Pfizer Viagra efficacy shown in broad range of subpopulations-labelling FDC reports-Pink Sheet-Prescription Pharmaceuticals and Biotechnology. *Mar* 1998;60:3-4
- [34] Carlson R. Sildenafil: an effective oral drug for impotence. *Inpharma.* 1997;1085:11–12. [[Google Scholar](#)]
- [35] The statement issued by expert panel of American College of Cardiology and American Heart Association. Aug 1998
- [36] Rosen RC, Riely A, Wagner G, Osterloh IH, Kirkpatrick I, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assesment of erectile dysfunction. *Urology.* 1997;49:422–430. doi: 10.1016/s0090-4295(97)00238-0. [[DOI](#)] [[PubMed](#)] [[Google Scholar](#)]
- [37] Goldstein I, Flue T, Padma-Nathan H, Rosen RC, Sters WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. *N Eng J Med* 1998;338:1397-404 [[DOI](#)] [[PubMed](#)]
- [38] Steers WD. Sildenafil study groupMeta-analysis of efficacy of sildenafil in the treatment of severe erectile dysfunction. *J Urol.* 1998;159(Suppl):238. [[Google Scholar](#)]
- [39] Wagner G, Maytom M, Smith MD. Multicentre study Group. Analysis of the efficacy of sildenafil in the treatment of male erectile dysfunction in the elderly. *J Urol* 1998;159(suppl): 239
- [40] Rendell MS, Moreno F. A double-blind, placebo-controlled, flexible dose-escalation studyAssessing the efficacy and safety of sildenafil in men with erectile dysfunction and diabetes. *Diabetes.* 1998;47(suppl):9. [[Google Scholar](#)]
- [41] Sildenafil efficacious for erectile dysfunction linked to spinal cord injuries. *Reuters Health* (on line) 1997



10.22214/IJRASET



45.98



IMPACT FACTOR:
7.129



IMPACT FACTOR:
7.429



INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089  (24*7 Support on Whatsapp)